Who is at higher risk for developing epistaxis?

• A. Patients with asthma
• B. Patients on anticoagulant therapy
• C. Patients with diabetes
• D. Patients with hypertension

Answer: (B)

Individuals on anticoagulant therapy are at higher risk for developing epistaxis, or nosebleeds, because anticoagulants work by thinning the blood and preventing it from clotting effectively. This means that even minor injury to the nasal mucosa, which is highly vascular, can lead to significant bleeding. The use of anticoagulants increases the likelihood of bleeding episodes, making such patients more susceptible to experiencing epistaxis.

In contrast, while patients with asthma, diabetes, and hypertension may experience other complications, they are not specifically linked to an increased risk of nosebleeds in the same way that anticoagulant users are. Asthma, for instance, relates to airway constriction and inflammation rather than blood clotting issues. Diabetes can lead to various complications, but it does not directly predispose someone to nosebleeds. Hypertension, although it may have effects on the vascular system, does not universally increase the risk of bleeding in the mucosal tissues like anticoagulant therapy does. Thus, the increased risk associated with anticoagulant use clearly identifies these patients as the group more likely to experience epistaxis.